Nektar Therapeutics (NKTR)
73.62
-2.34
(-3.07%)
USD |
NASDAQ |
May 14, 15:18
Nektar Therapeutics Cash from Investing (Quarterly) : -350.79M for March 31, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Eli Lilly & Co. | -3.916B |
| Aquestive Therapeutics, Inc. | -0.085M |
| Boston Scientific Corp. | -591.00M |
| Esperion Therapeutics, Inc. | -0.189M |
| Corcept Therapeutics, Inc. | 4.542M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -44.30M |
| Cash from Financing (Quarterly) | 529.55M |
| Free Cash Flow | -203.94M |
| Free Cash Flow Per Share (Quarterly) | -1.792 |
| Free Cash Flow to Equity (Quarterly) | -38.84M |
| Free Cash Flow to Firm (Quarterly) | -36.36M |
| Free Cash Flow Yield | -14.20% |